Results : This systematic review will provide a detailed summary of present evidence related to the efficacy and safety  of etoricoxib for patients with AS .
Conclusion : The results of this study may provide management guidance for AS treated by etoricoxib .
Background : Previous clinical trials have reported that etoricoxib has been utilized to treat ankylosing spondylitis ( AS ) effectively .
However , no study systematic ally investigated the efficacy and safety of etoricoxib for patients with AS .
In this systematic review , we will assess the efficacy and safety of etoricoxib for AS .
[Etoricoxib in the treatment of active sacroiliitis in patients with axial spondyloarthritis, including ankylosing spondylitis].
AIM To study a trend in active sacroiliitis ( ASI ) in patients with axial spondyloarthritis ( axSpA ) during different short-term regimens using etoricoxib ( ET ) 90 mg . SUBJECTS AND METHODS Forty patients with axSpA , including 30 with ankylosing spondyloarthritis ) , and ASI ( sacroiliac joint ( SIJ ) osteitis as evidence d by magnetic resonance imaging ) were examined and then r and omized to 2 groups : 1 ) 20 patients who took ET 90 mg four days or more a week ; 2 ) 20 patients who received ET 90 mg 3 days or less a week .  Osteitis was measured in 4 quadrants of each SIJ ( 0 - 3 scores ) . Its main criterion was considered to be a decrease in total osteitis activity ( TOA ) 12 week later . RESULTS In all the patients ( n = 40 ) , TOA decreased from 6.5 ( 4 ; 9 ) to 2 ( 0 ; 5 ) scores ( p < 0.0001 ) . In Group 1 ( n = 20 ) , that reduced from 6.5 ( 4 ; 8.5 ) to 0 ( 0 ; 3 ) scores ( p < 0.0001 ) . In Group 2 ( n = 20 ) , that did from 6.5 ( 4 ; 10 ) to 4 ( 1 ; 8) scores ( p = 0.49 ) . At 12 weeks , in in Groups 1 and 2 , the difference in final TOA achieved no statistical significance ( p=0.056 ) . In these groups , there were 19 ( 95 % ) and 14 ( 70 % ) treatment-responsive patients , respectively . CONCLUSION The intake of ET 90 mg for 12-weeks is associated with a reduction in the degree of ASI in patients with axSpA. The use of ET 4 times or more a week is more effective in diminishing osteitis than that of ET 3 days or less
Results : This systematic review will provide a detailed summary of present evidence related to the efficacy and safety  of etoricoxib for patients with AS .
Conclusion : The results of this study may provide management guidance for AS treated by etoricoxib .
Background : Previous clinical trials have reported that etoricoxib has been utilized to treat ankylosing spondylitis ( AS ) effectively .
However , no study systematic ally investigated the efficacy and safety of etoricoxib for patients with AS .
In this systematic review , we will assess the efficacy and safety of etoricoxib for AS .